| abstract |
Vaccine compositions and methods of use are described herein. In one embodiment, the vaccine composition comprises a RSV F protein in combination with an adjuvant. In a more particular embodiment, the vaccine composition comprises an RSV soluble F protein in combination with a lipid-like receptor (TLR) agonist. In a more particular embodiment, the adjuvant comprises glucopyranosyl lipid A (GLA). In a further embodiment, the adjuvant comprises GLA (GLA-SE) in a stable oil-in-water emulsion. |